Misinformation Has Created a New World Disorder

www.scientificamerican.com /article/misinformation-has-created-a-new-world-disorder/
Claire Wardle
18-23 minutes
As someone who studies the impact of misinformation on society, I often wish the young entrepreneurs of Silicon Valley who enabled communication at speed had been forced to run a 9/11 scenario with their technologies before they deployed them commercially.

One of the most iconic images from that day shows a large clustering of New Yorkers staring upward. The power of the photograph is that we know the horror they're witnessing. It is easy to imagine that, today, almost everyone in that scene would be holding a smartphone. Some would be filming their observations and posting them to Twitter and Facebook. Powered by social media, rumors and misinformation would be rampant. Hate-filled posts aimed at the Muslim community would proliferate, the speculation and outrage boosted by algorithms responding to unprecedented levels of shares, comments and likes. Foreign agents of disinformation would amplify the division, driving wedges between communities and sowing chaos. Meanwhile those stranded on the tops of the towers would be livestreaming their final moments.

More Encouraging Signs for Remdesivir as COVID-19 Treatment

Alice Park
5-7 minutes
Comment from the owner: What a pitty TIME...
Researchers at University of Chicago reported promising results from a small study of remdesivir in treating people with COVID-19.

The findings were not published in a peer-reviewed journal, but revealed in an internal video discussion of the drug trial among University of Chicago faculty that was obtained by STAT.

The study included 125 people with COVID-19, all of whom were treated with the remdesivir, which is not currently approved in the U.S. for treating any disease. Of the 125 patients in the Chicago study, 113 had severe disease, meaning they had difficulty breathing. In the video discussion, Kathleen Mullane, a professor of medicine at the university who is overseeing the trial, said most of the patients taking the drug had improved enough to be discharged from the hospital, and only two died. Mullane was not available to discuss the results, but in a statement, a university spokesperson said “Partial data from an ongoing clinical trial is by definition incomplete and should never be used to draw conclusions about the safety or efficacy of a potential treatment that is under investigation. In this case, information from an internal forum for research colleagues concerning work in progress was released without authorization. Drawing any conclusions at this point is premature and scientifically unsound.”